Alien: Earth review – TV that bristles with bone-deep dread
We are in the year 2120, just the right setting for a show that plays on our fears that our grandchildren and great-grandchildren are going to live in hell. Simple green-on-black text, styled like a computer readout from the 80s, informs us that, in this broken future, corporations have taken over the universe, and which one achieves total domination will be determined by which of three technologies wins a 'race for immortality': cyborgs (enhanced humans), synths (wholly artificial beings) or hybrids (synthetic bodies with human consciousnesses implanted).
The last of these is our primary concern in a first episode that mostly consigns the flesh-ripping aliens to flash-forwards so rapid they are almost subliminal. In Neverland, the laboratory complex of trillion-dollar disruptive startup Prodigy, a girl who looks to be in the last stages of terminal cancer lies down next to an inert adult figure she names Wendy. When the procedure is over, her brain has been copied from her ailing body and pasted into the entirely lifelike synthetic woman. The newly alive Wendy (Sydney Chandler) is the first hybrid and, soon, the leader of a gang of child-robot soldiers mentored by the enigmatic Kirsh, played by Timothy Olyphant sporting harrowing bleach-blond hair, an unnerving murmur and a turtleneck sweater that says something really isn't right here.
Up in space, meanwhile, a crew of humans have signed up for a job with big workers' rights issues. If being managed by a humourless cyborg named Morrow (Babou Ceesay) wasn't appalling enough, their cargo of captured alien life-forms are about to break out of the laughably weak glass containers they've been stored in, kill everyone except the self-preserving Morrow, and cause the spaceship to crash as Morrow grimly tries to fulfil his obligation to the super-rich Weyland-Yutani Corporation by returning the bounty to Earth.
As the ship mingles with the rubble of the tall urban Earth building it has ploughed into and a Prodigy search-and-rescue (-and-steal-anything-valuable) team descends, led by Alex Lawther as listless medic (and Wendy's long-lost brother!) Hermit, the monsters are finally on the loose. The setup is loose compared with most of the Alien movies, since the human and humanoid protagonists aren't confined with the creatures in a tin box surrounded by an endless, scream-proof void, so Alien: Earth has to find other ways to create bone-deep dread.
Most obviously we have the aliens, who aren't yet particularly innovative but are suitably awesome, from a scuttling, leechlike bug to an eyeball with many, many legs and a shiny xenomorph that comes over as a little more man-like than its previous incarnations. They're the classic nightmare fuel updated and sharpened and, when they strike, they leave behind the sort of oddly beautiful tableaux of torn corpses we haven't seen since Hannibal.
Sign up to What's On
Get the best TV reviews, news and features in your inbox every Monday
after newsletter promotion
Even better is the casting, with Lawther bringing the same blank resignation he lent to The End of the F***ing World, and Chandler offsetting it with a disturbing blend of naivety and concealed power. In an obvious allegory for the rise of AI, the hybrid Wendy has been given abilities beyond what even her creators understand. Most pleasing to see is Samuel Blenkin, rewarded for his fantastic supporting turn as the resentful weakling Prince Charles in Mary & George with the key role of Boy Kavalier, the 'genius' CEO of Prodigy and the Neverland project. With his comfy robes and puppyish, young-Wonka bounce, he is the frighteningly influential tech-bro pseudo-visionary who might bring the whole world crashing down, essentially just for a laugh: one of many nice touches in Blenkin's performance is the way the Boy takes a crucial video call by lying on a bed and gripping a tablet between his raised bare feet.
What Alien: Earth lacks in its opening two instalments is a propulsive, linear narrative or clarity of thematic vision, to the point where it sometimes approaches Westworld levels of making us ask the gloomy screen what in the blazes is happening. But whether it's a padded corridor filmed at a 10-degree angle, a landscape of jagged concrete and raining sparks, a wriggling creepy-crawly from space or just the look in someone's jaded eye, the series always has a way of making us feel like helpless prey being circled. Something gloriously horrific is just around the corner.
Alien: Earth is on Disney+ now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
16 minutes ago
- Reuters
THL Partners to acquire clinical trial firm Headlands from KKR, sources say
NEW YORK, Aug 14 (Reuters) - Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical trial sites, from KKR (KKR.N), opens new tab in a deal valued at about $600 million, according to people familiar with the matter. The transaction could be announced as soon as Thursday, the sources said. Clinical trial sites are experiencing steady business growth as pharmaceutical companies ramp up research spending, driven by new types of therapies and the growing healthcare needs of an aging population. Private equity firms have stepped up their involvement in clinical trials, drawn by the potential to leverage technology to scale operations and consolidate a fragmented network of stand-alone sites into more integrated and valuable platforms. THL has been active in pharma services for more than two decades, with past investments including Syneos Health, PCI Pharma Services, Adare Pharma Solutions, and Red Nucleus. The transaction marks an exit for private equity firm KKR, which acquired Headlands in 2018 and is said to have at least doubled its investment, according to a person familiar with the matter. KKR's exit in Headlands followed its successful $12 billion divestment of PRA Health Sciences, a clinical research organization where it delivered a sixfold return for investors. Recent deals by private equity firms in clinical trials include BayPine's $1.5 billion acquisition of CenExel, and Genstar Capital's majority investment in Flourish Research, for an undisclosed amount. AI is accelerating drug discovery and development, and private equity firms are betting that faster approvals of new therapies will boost demand for clinical trials. Headlands operates more than 20 sites and has conducted over 5,000 trials in therapeutic areas including central nervous system disorders, mental health, vaccines, and metabolic diseases.
The Guardian
16 minutes ago
- The Guardian
Ben Beaumont-Thomas's album of the week
As bloated piles of 'content' overfill our cultural to-do lists, a double album isn't always met with a warm welcome: an 80-minute film is seen as lean, but an LP of the same length is seen as an exasperating slog. But if anyone can change this mindset it's the US singer-songwriter Cass McCombs, whose 74-minute new double LP begins at the highest songwriting level and barely wavers. McCombs' career stretches back to the early 00s, and this unassuming 47-year-old has steadily walked the valley floor of US indie ever since, often overlooked compared to his hyped peers, but perhaps with a longer career for it. This is his 11th album, not counting compilations, collaborations and a terrific posthumous album by New Hollywood icon Karen Black, which he oversaw. The centre of his palette has always been folk-rock but the edges have held other imaginatively mixed colours: the vocal to his 2007 song That's That, a tale of youthful romance leading to a job as a toilet cleaner in a Baltimore nightclub, could have been crooned over pedal steel by a mid-century country star; his 2009 duet with Black, Dreams-Come-True-Girl, sounds like it's been beamed from a homecoming dance in 1955. Amid his poetic, sometimes gnomic lyrics would come real-world details: in 2012 he told whistleblower Chelsea Manning's story in song, while New Earth – from his previous and, until now, best album Heartmind – addressed Elon Musk, heralding a bright post-apocalyptic world where 'orchids mock him, spread so wide / With a lurid flavour his foul name could not hide'. That particularity and plurality is all over Interior Live Oak, full of dreamscapes anchored in real-world settings (New York's George Washington Bridge, San Francisco's Transamerica Pyramid), and backings that are both classically American but also have their own weird back-country accent. The album opens with Priestess, an ode to a late friend that harks back to McCombs's California youth, again with specific detail amid strange painterly settings: 'In our seminary of contradictions / Ella Fitzgerald, thizz and whippits / you were our priestess.' It's core McCombs mode, grooving along in a slow lupine lope, rather like his best-known song Bum Bum Bum. It gives us the first tear-jerking moment, too, as McCombs yearns to hear his friend sing John Prine's Angel from Montgomery one more time. There are more tears to be shed on piano-driven ballad I Never Dream About Trains, in which our narrator affects not to care about a lost love, his protests underscoring the devastation: 'I never dream about you curled up in that old army jacket / On the sand in Pescadero / I never lie in my songs / And I never dream about trains.' You can imagine Tony Bennett or Frank Sinatra singing it, or another waltzing number, Strawberry Moon. The very best of the ballads is Missionary Bell, a song whose melody is so simple and expressive you can scarcely believe it hasn't always existed. The bells of the title sound across a landscape of 'wild fennel in the wetlands, nightfall hurling down', as McCombs again considers death and the people it leaves behind. The album's long runtime means that these all feel wonderfully unhurried, and it gives McCombs space for other expansive, ruminative songs. Asphodel putters along at the pace of the Modern Lovers' Roadrunner, considering yet another dead friend as McCombs travels through a mystical bardo; Who Removed the Cellar Door? has the twang and wide-angled lens of spaghetti westerns; Lola Montez Danced the Spider Dance is a slow ritualistic stomp with the nihilism and dry heat of a Lorca play. Diamonds in the Mine is a grownup existential lullaby you might sing to a troubled partner; Peace has an acoustic guitar riff of extraordinary dexterity and prettiness; Juvenile, a funny song that throws two fingers up at soulless ad men, is powered by a Devo-style organ line you'll be humming all week. If anything, as the title track's nervy Dylanesque fuzz-rock brings everything to an end, 74 minutes doesn't feel remotely long enough with McCombs on this sort of form. Llondon Actress – Moscow'I'm a dragonfly, you're a cockroach!' The 11th single this year from the young UK rapper-producer delivers on its boasts: a prowling cloud rap track with a repeated vocal melody pulsating through the fug. His new EP Billionaire Supervillain has also just been released.
Daily Mail
16 minutes ago
- Daily Mail
The race to link our brains with AI: Inside Elon Musk and Sam Altman's battle to be first to connect mind and machine
The tussles between billionaires have seen vast fortunes splashed on everything from rocket ships to social media empires. But now, two titans of big tech are taking their fight to a frontier: The race to link our brains with AI. Tesla and xAI CEO Elon Musk and Sam Altman of OpenAI, the company behind ChatGPT, are vying to be the first to connect mind and machine. The former allies are now both backing rival companies trying to build brain-computer-interface (BCI) chips and put them inside humans. These devices allow people to directly control computers with their thoughts by reading the electrical signals produced in the brain. As outspoken champions of the technology, both Mr Musk and Mr Altman claim that BCIs will one day allow humanity to merge with artificial intelligence. Elon Musk's Neuralink, widely seen as the leader in the BCI field, has already tested its brain chips on patients in the US and has secured plans for UK trials. However, as reported by the Financial Times, Mr Altman is now planning to back rival firm Merge Labs with a plan to make BCIs faster and more capable using AI. Not too long ago, Musk and Altman were close collaborators who co-launched OpenAI in 2015, with Musk providing the majority of the funds. However, the pair fell out three years later after Musk dramatically quit the board following an internal battle for control over the fast-growing firm. In the following years, Musk and Altman have waged an increasingly public rivalry. This culminated in Musk suing OpenAI to prevent the company from transitioning into a for-profit, alleging a 'deceit of Shakespearean proportions'. As Musk attempts to challenge OpenAI's supremacy in AI with his problem-plagued chatbot, Grok, the former colleagues are now shifting their rivalry into the world of BCIs. BCIs use AI to convert the patterns of electrical activity found in the brain into commands that a computer can understand. Advocates argue that they have the potential to help disabled people recover their independence by remotely controlling computers, bionic limbs, or mobility aids. This technology has even gained the attention of governments, with the UK's Advanced Research and Invention Agency exploring its potential as part of a mission to explore devices that could change the world. Likewise, the Chinese Ministry of Industry and Information Technology has revealed its own BCI, used to restore hand movement in paralysed patients. Neuralink, which was founded in 2016, is leading the field for computer-brain connection research while rival startups, such as Precision Neuroscience, vie to compete. Neuralink uses a coin-sized computer chip containing 1,000 electrodes, separated into 128 tiny 'threads' each thinner than a human hair. Using a robotic surgeon, also being developed by Neuralink, the chip is placed on the surface of the brain, and the threads are inserted into the neural tissue. The chip, known as the N1, uses these electrode threads to record huge amounts of data on the brain's activity and uses AI to translate those signals. Neuralink began human trials in America last year, implanting a chip into its first human volunteer, Noland Arbaugh, who was paralysed from the neck down in a driving accident. Using the chip, Mr Arbaugh regained the ability to control a computer, enabling him to write, play chess, and even play complex video games. Since then, the company has implanted chips in a further six participants in the United States and recently received approval to recruit a further seven patients for a British study, the first of its kind in Europe. Neuralink has now implanted chips into seven patients in the United States, including Audrey Crews (pictured), who has been paralysed since she was 16 Recently, the company raised $650 million (£478m) in a funding deal, which gave it a valuation of $9 billion (£6.63bn). By contrast, very little is known about Mr Altman's rival firm, Merge Labs. Mr Altman reportedly plans to launch the company alongside his long-term collaborator Alex Blania, who runs the Altman-backed eyeball scanning digital ID project, Worldcoin. It is expected that Mr Altman will help found the company, but won't have a day-to-day role in its operations. The exact form of BCI technology Merge Labs plans to pursue remains a mystery; beyond the fact that it will make the most of recent AI advances to improve BCI function. Merge Labs is reportedly seeking $250 million (£184m) in initial funding, much of which is expected to be provided by OpenAI's ventures arm, giving the company an initial valuation of $850 million (£625m). However, despite their rivalry, both Mr Musk and Mr Altman appear to be pursuing BCI technology with a similar goal in mind. Mr Musk has said that his ambition is to make a 'general population device' that will allow for 'symbiosis with artificial intelligence'. Sam Altman wrote in a 2017 blog that merging with AI was the only way to avoid fading into an, 'evolutionary tree branch' as AI overtakes human intelligence The billionaire X owner has also insinuated that merging with computers is necessary to prevent super-intelligent AI from getting out of control. Similarly, Mr Altman wrote in a 2017 blog post titled 'The Merge' that humans and machines would become one between 2025 and 2075. In the blog, Mr Altman wrote: 'The merge can take a lot of forms: We could plug electrodes into our brains, or we could all just become really close friends with a chatbot. But I think a merge is probably our best-case scenario. 'My guess is that we can either be the biological bootloader for digital intelligence and then fade into an evolutionary tree branch, or we can figure out what a successful merge looks like.' Elon Musk's Neuralink is working to link the human brain with a machine interface by creating micron-sized devices. Neuralink was registered in California as a 'medical research' company in July 2016, and Musk has funded the company mostly by himself. It is working on what Musk calls the 'neural lace' technology, implanting tiny brain electrodes that may one day upload and download thoughts. The technology is initially planned to be used to help people suffering from severe degenerative brain disorders such as ALS, but it could have wider uses in years to come.
